AT-130

• CAT Number: I003020
• CAS Number: 211364-06-6
• Molecular Formula: C22H22BrN3O5
• Molecular Weight: 488.34
• Purity: ≥95%
• Synonyms: AT-130; AT 130; AT130.;(E)-N-(1-bromo-1-(2-methoxyphenyl)-3-oxo-3-(piperidin-1-yl)prop-1-en-2-yl)-4-nitrobenzamide
• IUPAC Name: N-[(E)-1-bromo-1-(2-methoxyphenyl)-3-oxo-3-piperidin-1-ylprop-1-en-2-yl]-4-nitrobenzamide
• InChI: InChI=1S/C22H22BrN3O5/c1-31-18-8-4-3-7-17(18)19(23)20(22(28)25-13-5-2-6-14-25)24-21(27)15-9-11-16(12-10-15)26(29)30/h3-4,7-12H,2,5-6,13-14H2,1H3,(H,24,27)/b20-19+
• InChIKey: OQIUTYABZMBBME-FMQUCBEESA-N
• SMILES: COC1=CC=CC=C1C(=C(C(=O)N2CCCCC2)NC(=O)C3=CC=C(C=C3)[N+](=O)[O-])Br

AT-130（Cat No.:I003020）is a novel investigational compound designed to target and modulate the activity of protein kinases involved in cell signaling pathways. By selectively inhibiting these kinases, AT-130 aims to disrupt abnormal signaling processes associated with various cancers and inflammatory diseases. Its precise mechanism of action helps to reduce tumor growth and inflammation, making it a promising candidate for targeted therapy. With its potential to improve treatment outcomes and minimize side effects, AT-130 is under extensive research for its efficacy and safety in oncology and immunology therapeutic development.